Sponsors (7)
The bill strengthens newborn screening systems, data, research, and parent-facing education to improve early detection and follow-up, but does so at the cost of increased federal/state spending, administrative burdens, and notable privacy and governance trade-offs for families and local programs.
Newborn screening programs and state health systems will get standardized, near–real-time data and enhanced CDC support (new tests, lab best-practices, analysis tools), improving early detection, diagnostic accuracy, and follow-up for infants nationwide.
Parents and families will receive clearer, literacy‑appropriate, measured educational programs and outreach that facilitate follow-up and care coordination, increasing understanding of newborn screening and improving linkage to services.
The process for nominating conditions to the newborn screening panel and associated conflict-of-interest rules will be more transparent and consumer‑friendly, improving access to nomination pathways and public trust in decisionmaking.
Infants and families face increased privacy risks because the bill enables near–real‑time EHR/data linkage and expanded federal data collection without commensurate, specified new privacy safeguards.
Parents and individuals may have reduced control over newborn dried blood spots because broader secondary use of deidentified specimens could occur without consent, raising privacy and trust concerns.
Taxpayers, states, and health systems could face substantial new administrative, IT, and program costs (communications, data systems, pilots, expanded testing activities) to comply with reporting, measurement, and standardization requirements.
Based on analysis of 8 sections of legislative text.
Updates federal newborn screening law to expand education/follow‑up, strengthen advisory guidance and surveillance, authorize lab/test development, and classify nonidentified dried blood‑spot research as secondary research.
Introduced July 23, 2025 by Kelly Morrison · Last progress July 23, 2025
Updates and reauthorizes federal newborn screening policy by expanding education and follow-up duties, strengthening advisory committee guidance, improving laboratory and surveillance activities, changing research classification for nonidentified dried blood spots, and adjusting program authorization/funding language. It directs the Department of Health and Human Services (through CDC and advisory bodies) to standardize data collection and reporting, enhance test-development and performance-evaluation activities, require certain program assurances, and publish consumer-facing nomination guidance for the uniform screening panel.